Study MAG104615, a Proof of Concept Study for GSK249320 Versus Placebo in Stroke Patients

Trial Profile

Study MAG104615, a Proof of Concept Study for GSK249320 Versus Placebo in Stroke Patients

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Refanezumab (Primary)
  • Indications Stroke
  • Focus Proof of concept; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 24 Feb 2017 Results presented at the 42nd International Stroke Conference
    • 22 Feb 2017 Primary endpoint (Mean change in gait velocity) has not been met, according to the results published in the Stroke.
    • 22 Feb 2017 Results published in the Stroke
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top